102989-24-2|Asimicin|(S)-3-((2R,13R)-2,13-dihydroxy-13-((2R,2'R,5R,5'R)-5'-((R)-1-hydroxyundecyl)octahydro-[2,2'-bifuran]-5-yl)tridecyl)-5-methylfuran-2(5H)-one|-范德生物科技公司

Asimicin

NMR下载 COA and HPLC MSDS下载
names：
(S)-3-((2R,13R)-2,13-dihydroxy-13-((2R,2'R,5R,5'R)-5'-((R)-1-hydroxyundecyl)octahydro-[2,2'-bifuran]-5-yl)tridecyl)-5-methylfuran-2(5H)-one
CAS号：
102989-24-2
MDL Number：
MF(分子式)： C37H66O7 MW(分子量)： 622.92
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Asimicin
英文别名	Asimicin;
CAS号	102989-24-2
Inchi	InChI=1S/C37H66O7/c1-3-4-5-6-7-11-14-17-20-31(39)33-22-24-35(43-33)36-25-23-34(44-36)32(40)21-18-15-12-9-8-10-13-16-19-30(38)27-29-26-28(2)42-37(29)41/h26,28,30-36,38-40H,3-25,27H2,1-2H3/t28-,30+,31+,32+,33+,34+,35+,36+/m0/s1
InchiKey	MBABCNBNDNGODA-UOCXRWNNSA-N
分子式 Formula	C37H66O7
分子量 Molecular Weight	622.92
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Asimicin(CAS:102989-24-2):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Asimicin is a potent complex I inhibitor.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Mangal M, Khan MI, Agarwal SM. Acetogenins as Potential Anticancer Agents. Anticancer Agents Med Chem. 2015;16(2):138-59. Review. PubMed PMID: 26118710.

[2]Nakamaru-Ogiso E, Han H, Matsuno-Yagi A, Keinan E, Sinha SC, Yagi T, Ohnishi T. The ND2 subunit is labeled by a photoaffinity analogue of asimicin, a potent complex I inhibitor. FEBS Lett. 2010 Mar 5;584(5):883-8. doi: 10.1016/j.febslet.2010.01.004. Epub 2010 Jan 13. PubMed PMID: 20074573; PubMed Central PMCID: PMC2836797.

[3] Zhao GX, Miesbauer LR, Smith DL, McLaughlin JL. Asimin, asiminacin, and asiminecin: novel highly cytotoxic asimicin isomers from Asimina triloba. J Med Chem. 1994 Jun 24;37(13):1971-6. PubMed PMID: 8027979.

[4] Avedissian H, Sinha SC, Yazbak A, Sinha A, Neogi P, Sinha SC, Keinan E. Total synthesis of asimicin and bullatacin. J Org Chem. 2000 Sep 22;65(19):6035-51. PubMed PMID: 10987938.

[5] Shimada H, Grutzner JB, Kozlowski JF, McLaughlin JL. Membrane conformations and their relation to cytotoxicity of asimicin and its analogues. Biochemistry. 1998 Jan 20;37(3):854-66. PubMed PMID: 9454575.

6: Zhao GX, Chao JF, Zeng L, Rieser MJ, McLaughlin JL. The absolute configuration of adjacent bis-THF acetogenins and asiminocin, a novel highly potent asimicin isomer from Asimina triloba. Bioorg Med Chem. 1996 Jan;4(1):25-32. PubMed PMID: 8689234.7: Ye Q, He K, Oberlies NH, Zeng L, Shi G, Evert D, McLaughlin JL. Longimicins A-D: novel bioactive acetogenins from Asimina longifolia (annonaceae) and structure-activity relationships of asimicin type of annonaceous acetogenins. J Med Chem. 1996 Apr 26;39(9):1790-6. PubMed PMID: 8627602.8: Marshall JA, Sabatini JJ. An outside-in approach to adjacent bistetrahydrofuran annonaceous acetogenins with C2 core symmetry. Total synthesis of asimicin and a C32 analogue. Org Lett. 2006 Aug 3;8(16):3557-60. PubMed PMID: 16869659.9: Sinha SC, Chen Z, Huang ZZ, Nakamaru-Ogiso E, Pietraszkiewicz H, Edelstein M, Valeriote F. Alteration of the bis-tetrahydrofuran core stereochemistries in asimicin can affect the cytotoxicity. J Med Chem. 2008 Nov 27;51(22):7045-8. doi: 10.1021/jm801028c. PubMed PMID: 18975929; PubMed Central PMCID: PMC2670474.10: Tinsley JM, Roush WR. Total synthesis of asimicin via highly stereoselective [3 + 2] annulation reactions of substituted allylsilanes. J Am Chem Soc. 2005 Aug 10;127(31):10818-9. PubMed PMID: 16076173.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开